{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pino M"],"funding":["National Institute of Allergy and Infectious Diseases","Office of Public Affairs","Childhood Infections and Vaccines Children Healthcare of Atlanta 712 Woodruff Health Sciences Center","NIAID NIH HHS","Baylor University","Yerkes National Primate Research Center, Emory University","National Institutes of Health","Scientific Advisory Board of MaxHealth 724 Biotechnology LLC","NIH HHS"],"pagination":["eabh3634"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9119307"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(61)"],"pubmed_abstract":["Ongoing SARS-CoV-2 vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low and middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast expressed SARS-CoV-2 specific receptor-binding domain (RBD) based vaccine in rhesus macaques. We formulated the RBD immunogen in alum, a licensed and an emerging alum adsorbed TLR-7/8 targeted, 3M-052-alum adjuvants. The RBD+3M-052-alum adjuvanted vaccine promoted better RBD binding and effector antibodies, higher CoV-2 neutralizing antibodies, improved Th1 biased CD4+T cell reactions, and increased CD8+ T cell responses when compared to the alum-alone adjuvanted vaccine. RBD+3M-052-alum induced a significant reduction of SARS-CoV-2 virus in respirat"],"journal":["Science immunology"],"pubmed_title":["A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates."],"pmcid":["PMC9119307"],"funding_grant_id":["75N9301900065","22206","3U19AI057266-17S1","U19 AI057266","TLR-7/8 723","US 2019/0142935","P51 OD011132","U19 AI090023","HHSN272201800004C","2020 COVID-19 CURE A","P30 A050509","ORIP/OD P51OD011132","3U19AI057266-715","HIPC COVID-19 S","COVID-19 RBD","P51-OD011132","U19AI090023"],"pubmed_authors":["Pacheco-Sanchez G","Gumber S","Jean SM","Sette A","Paiardini M","Pollara J","Mielke D","Lee J","Gao H","Wood JS","Suthar MS","Abid T","Liu Z","Dutta D","Edara VV","Wang S","Strych U","Shenvi N","Sekaly RP","Hotez PJ","Montefiori DC","Stammen RL","Wei J","Shen X","Smith JC","Connor-Stroud F","Kasturi SP","Vanderford TH","Pollet J","Zhan B","Latif MB","Tomai MA","Pereira Ribeiro S","Ferrari G","Bottazzi ME","Floyd K","Weiskopf D","Kozlowski PA","Kirejczyk S","LaBranche CC","Fox CB","Chen WH","Easley K","Pino M","Eisel N","Cohen J","Tomaras GD"],"additional_accession":[]},"is_claimable":false,"name":"A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.","description":"Ongoing SARS-CoV-2 vaccine development is focused on identifying stable, cost-effective, and accessible candidates for global use, specifically in low and middle-income countries. Here, we report the efficacy of a rapidly scalable, novel yeast expressed SARS-CoV-2 specific receptor-binding domain (RBD) based vaccine in rhesus macaques. We formulated the RBD immunogen in alum, a licensed and an emerging alum adsorbed TLR-7/8 targeted, 3M-052-alum adjuvants. The RBD+3M-052-alum adjuvanted vaccine promoted better RBD binding and effector antibodies, higher CoV-2 neutralizing antibodies, improved Th1 biased CD4+T cell reactions, and increased CD8+ T cell responses when compared to the alum-alone adjuvanted vaccine. RBD+3M-052-alum induced a significant reduction of SARS-CoV-2 virus in respirat","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-09T15:04:56.79Z","creation":"2025-04-04T08:38:53.627Z"},"accession":"S-EPMC9119307","cross_references":{"pubmed":["34266981"],"doi":["10.1126/sciimmunol.abh3634"]}}